Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2007

GSK Licenses BioWa Tool for Antibody R&D

  • GlaxoSmithKline (GSK) gained access to BioWa's Potelligent® technology for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

    The agreement grants GSK nonexclusive rights to research and develop antibodies based on this platform for an undisclosed number of targets. In return, BioWa will receive an upfront payment and license fees.

    Potelligent improves potency and efficacy of antibody therapeutics by enhancing ADCC, according to BioWa. It reduces the amount of fucose in the carbohydrate structure of an antibody using a fucosyltransferase-knockout CHO cell line as a production cell.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »